Prof. Sun Young Rha, Professor of Medical Oncology, Yonsei University College of Medicine, South Korea
In HER2-positive gastric and gastroesophageal adenocarcinoma, the HERIZON-GEA-01 trial found that zanidatamab-based therapy improved survival consistently across patients regardless of PD-L1 status. Prof. Rha examines the mechanism behind this PD-L1-independent efficacy and weighs in on whether TAP or CPS scoring better serves pathological screening in real-world first-line practice. She also considers what heavy crossover therapy in the control arm reveals about the case for front-loading the most potent combination from the start.